Japan Crispr And Cas Genes Market Size & Outlook
Japan crispr and cas genes market, 2018-2030 (US$M)
Related Markets
Japan crispr and cas genes market highlights
- The Japan crispr and cas genes market generated a revenue of USD 237.2 million in 2024 and is expected to reach USD 624.1 million by 2030.
- The Japan market is expected to grow at a CAGR of 17.8% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 237.2 million |
| Market revenue in 2030 | USD 624.1 million |
| Growth rate | 17.8% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, Japan accounted for 5.1% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,162.8 million by 2030.
Product was the largest segment with a revenue share of 91.27% in 2024. Horizon Databook has segmented the Japan crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Changes in regulatory policies pertaining to gene editing, coupled with rapid adoption of advanced technologies by the country have resulted in its significant market share. In April 2016, the Japanese government’s bioethics panel approved DNA modification in human embryos of up to two weeks for basic research purposes.
In February 2019, in accordance with the Japanese Cartagena Act government, the government stated that genome-edited end products established from the modifications of SDN-1 type, a direct mutation, are not regarded as living modified organisms.
In August 2018, a Japanese government panel regulated only genetically modified organisms, where foreign genes are induced permanently, implying that the production of gene edited organisms will not require government approval.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan crispr and cas genes market size, by product & service, 2018-2030 (US$M)
Japan CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
